Collegium Pharmaceutical (COLL) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Evolus (EOLS) has outperformed Collegium Pharmaceutical (COLL) over the past year, gaining 25.6% versus a loss of 33.3%. Over five years, COLL leads with a +5.4% price change compared with +1.7% for EOLS. Collegium Pharmaceutical is the larger company by market cap ($719.8 million vs $515.2 million), about 1.4 times the size.
On valuation, Collegium Pharmaceutical trades at a lower forward P/E (3.3x vs 26.7x for Evolus).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | EOLS |
|---|---|---|
| Share price | $22.11 | $7.80 |
| Market cap | $719.80M | $515.19M |
| 1-day change | +0.82% | +0.78% |
| YTD return | -52.25% | +17.29% |
| 1-year return | -33.26% | +25.60% |
| 5-year return | +5.39% | +1.69% |
| P/E ratio (TTM) | 17.41 | — |
| Forward P/E | 3.33 | 26.67 |
| EPS (TTM) | $1.27 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.79 | $9.31 |
| 52-week low | $21.43 | $3.86 |
| Distance from 52-week high | -56.47% | -16.22% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +121.62% | +92.31% |
| Average volume | 749.33K | 900.79K |
| Shares outstanding | 32.56M | 66.05M |
| Employees | 423 | 353 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed COLL by 58.9 percentage points over the past year.
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
COLL vs EOLS FAQ
Which is bigger, Collegium Pharmaceutical or Evolus?
Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $719.80M compared with $515.19M for Evolus (EOLS).
Which stock has performed better over the past year, COLL or EOLS?
EOLS returned +25.60% over the past 12 months, compared with -33.26% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Collegium Pharmaceutical and Evolus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.